A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519437-27-02

Acronym

English

Enrollment

168

Registered

2025-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

The primary endpoint is overall survival

Detailed description

1) To determine the 6- and 12 months progression-free survival (PFS) 2) To determine the objective response rate (RR) and duration of response (according to RANO criteria). 3) To determine the overall survival distribution and overall survival at 12 and 18 months. 4) To determine the safety and feasibility of the combination of bevacizumab and lomustine as compared to lomustine alone.

Interventions

DRUGZirabev 25 mg/ml concentrate for solution for infusion.

DRUGLOMUSTINE MEDAC 40 mg

DRUGgélule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is overall survival	—

Secondary

Measure	Time frame
1) To determine the 6- and 12 months progression-free survival (PFS) 2) To determine the objective response rate (RR) and duration of response (according to RANO criteria). 3) To determine the overall survival distribution and overall survival at 12 and 18 months. 4) To determine the safety and feasibility of the combination of bevacizumab and lomustine as compared to lomustine alone.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026